BridgeMD
New treatment option for Acute Ischemic Stroke
Official title Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
ClinicalTrials.gov ID: NCT06045156
What this study is testing
What is Tirofiban?
Tirofiban is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age≥18 years old;
- Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset;
- Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;
- Tirofiban or placebo treatment can be initiated within 6h after IVT;
- mRS score before onset≤ 1;
You likely can't join if
- Received or plan to undergo bridge therapy;
- Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area);
- Atrial fibrillation or suspected cardiac embolism;
- Accompanied by epileptic seizures;
- Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment;
- Active bleeding or tendency to bleed after receipt of intravenous thrombolysis;
See the full eligibility criteria
- Age≥18 years old;
- Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset;
- Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;
- Tirofiban or placebo treatment can be initiated within 6h after IVT;
- mRS score before onset≤ 1;
- Intracranial hemorrhage is ruled out by CT head after IVT;
- Received or plan to undergo bridge therapy;
- Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area);
- Atrial fibrillation or suspected cardiac embolism;
- Accompanied by epileptic seizures;
- Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment;
- Active bleeding or tendency to bleed after receipt of intravenous thrombolysis;
- Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year;
- Severe renal or liver insufficiency; ALT or AST\>3 times of the upper limit of normal value or above; creatinine clearance rate\ 200μmol/L；
- Life expectancy less than 3 months;
- Pregnant or lactating women;
- Known allergy to tirofiban;
- Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.;
- Patients who are unwilling to be followed up or likely to have poor treatment compliance;
- Other situations that the researcher deems unsuitable for inclusion in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Changchun, Jilin, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Changchun, Jilin, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.